Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: A case series

Stefano Marenco, Michael F. Egan, Terry E. Goldberg, Michael B. Knable, Robert K. McClure, Georg Winterer, Daniel R. Weinberger

Research output: Contribution to journalArticle

Abstract

We used L-(quinoxalin-6-ylcarbonyl)piperidine (CX516) (a modulator of the α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid (AMPA) receptor) as a sole agent in a double blind placebo-controlled design in a small series of patients with schizophrenia who were partially refractory to treatment with traditional neuroleptics. The study entailed weekly increments in doses of CX516, from 300 mg tid for week 1 up to 900 mg tid on week 4. Patients were followed with clinical ratings, neuropsychological testing, and were monitored for adverse events. Four patients received 2 to 4 weeks of CX516, two received placebo and two withdrew during the placebo phase. Adverse events associated with drug administration were transient and included leukopenia in one patient and elevation in liver enzymes in another. No clear improvement in psychosis or in cognition was observed over the course of the study. CX516 at the doses tested did not appear to yield dramatic effects as a sole agent, but inference from this study is limited.

Original languageEnglish (US)
Pages (from-to)221-226
Number of pages6
JournalSchizophrenia Research
Volume57
Issue number2-3
DOIs
StatePublished - Oct 1 2002
Externally publishedYes

    Fingerprint

Keywords

  • AMPA
  • CX516
  • Clinical trial
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this